ArticleScientific reports2025
Therapeutic resistance and combination therapy for cancer: recent developments and future directions.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- RBM protein family: Focusing on the occurrence, progression and treatment of cancer.Medical oncology (Northwood, London, England) · 2026Review
- Ellagic Acid and Metformin: In Vitro Synergy and Enhanced Cisplatin Efficacy In Vivo in Resistant Breast Cancer.Nutrients · 2026Article
- Unlocking the potential of marine natural product fragments for rational anticancer drug design: a computational approach.Scientific reports · 2026Article
- Synergistic combinatorial anticancer potential of Tamoxifen with Naringin and Diosmetin in MCF-7 breast cancer cells and their liposomal delivery.Scientific reports · 2026Article
- Understanding Cancer Health Disparities.Cancers · 2026Review
- Key Tumor Responsive ZIF-8 Nanocarriers for Effective Anti-Cancer Therapeutics.International journal of nanomedicine · 2026Review
- Effects of atranorin on the proliferation, apoptosis and metastasis of two different gastric cancer cell lines and exploring underlying mechanisms.Molecular biology reports · 2025Article
- Nanomedicine and nutraceutical-based nanocarriers for specific delivery to cancer stem cells: targeted drug delivery at the STEM frontier.Discover oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.